.gif)
Eloquest Healthcare and Vancive Medical Technologies Launch Antimicrobial Post-Operative Dressings
- #AVY--Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY) business,
and Eloquest Healthcare®, Inc. have partnered to develop an
innovative post-operative dressing that contains an antimicrobial agent
called chlorhexidine gluconate (CHG). The antimicrobial properties of
CHG inhibit microbial growth within the dressing.
CHG is extremely difficult to incorporate in an absorbent adhesive dressing, making the development of the BeneHold™ CHG platform a significant technical accomplishment for Vancive. The Eloquest Healthcare ReliaTect™ Post-Op Dressings with CHG are the first to combine CHG in an absorbent, transparent and waterproof design.
“ReliaTect post-operative dressings are a natural fit for our BeneHold CHG platform, and the needs of patients and clinicians,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “We look forward to further expanding our CHG technology to many more applications.”
ReliaTect is available in small and large sizes with a transparent window for surgical site visualization, and a nonwoven border that facilitates dressing application and provides additional securement during wear. The dressings comfortably adhere to the skin, absorb fluids and protect the site from external contaminants.
“Chlorhexidine Gluconate (CHG) is a trusted antiseptic in pre-operative site treatment,” said Tim O’Halla, president and CEO for Eloquest Healthcare. “By combining its antimicrobial properties with the sustained transparency and absorbency of our ReliaTect Post-Op Dressings, we are bringing to market a truly patient friendly post-operative dressing with proven antimicrobial activity.”
ReliaTect Post-Op Dressings with CHG are now commercially available from Eloquest Healthcarein the United States. The device received 510(k) clearance from the FDA in March and is now available nationwide. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.
To learn more or request a sample visit, www.ReliaTectPostOp.com or contact Eloquest Healthcare customer service at 1-877-433-7626.
About Eloquest Healthcare
Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that complement treatment protocols. More information can be found at www.eloquesthealthcare.com.
About Vancive Medical Technologies
Vancive Medical Technologies is a medical technology company with more than three decades of expertise in adhesive chemistries and material technologies for medical applications using pressure sensitive adhesives. The company's applications and technologies are an integral part of products that are in daily use in medical facilities throughout the world. Through long-term relationships with original equipment manufacturers, industry-specific converters and leading universities, Vancive Medical Technologies continually finds new ways to develop products that can improve patient care. Vancive Medical Technologies is an Avery Dennison business headquartered in Chicago, Illinois. To learn more about Vancive Medical Technologies, visit www.vancive.averydennison.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in pressure-sensitive and functional materials and labeling solutions for the retail apparel market. The company’s applications and technologies are an integral part of products used in every major industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers in the consumer packaging, graphical display, logistics, apparel, industrial and healthcare industries. Headquartered in Glendale, California, the company reported sales of $6.1 billion in 2016. Learn more at www.averydennison.com.
ContactsEloquest Healthcare Contact:
Matthew Stahl
Clinical Marketing & Brand Director
248.586.8428
[email protected]
or
Vancive Contacts:
Andrew Deckert
Global Marketing Communications Manager
+1 224 374 2109
[email protected]
or
Barbara Van Rymenam
Global Director, CHG Program
+32 (0)497 103233
[email protected]
&source=" target="_blank" />
The FDA-cleared dressings are now commercially available in the
United States
FERNDALE, Mich.–(BUSINESS WIRE)–#AVY–Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY) business,
and Eloquest Healthcare®, Inc. have partnered to develop an
innovative post-operative dressing that contains an antimicrobial agent
called chlorhexidine gluconate (CHG). The antimicrobial properties of
CHG inhibit microbial growth within the dressing.
CHG is extremely difficult to incorporate in an absorbent adhesive
dressing, making the development of the BeneHold™ CHG platform a
significant technical accomplishment for Vancive. The Eloquest
Healthcare ReliaTect™ Post-Op Dressings with CHG are the first to
combine CHG in an absorbent, transparent and waterproof design.
“ReliaTect post-operative dressings are a natural fit for our BeneHold
CHG platform, and the needs of patients and clinicians,” said Kirsten
Newquist, general manager for Vancive Medical Technologies. “We look
forward to further expanding our CHG technology to many more
applications.”
ReliaTect is available in small and large sizes with a transparent
window for surgical site visualization, and a nonwoven border that
facilitates dressing application and provides additional securement
during wear. The dressings comfortably adhere to the skin, absorb fluids
and protect the site from external contaminants.
“Chlorhexidine Gluconate (CHG) is a trusted antiseptic in pre-operative
site treatment,” said Tim O’Halla, president and CEO for Eloquest
Healthcare. “By combining its antimicrobial properties with the
sustained transparency and absorbency of our ReliaTect Post-Op
Dressings, we are bringing to market a truly patient friendly
post-operative dressing with proven antimicrobial activity.”
ReliaTect Post-Op Dressings with CHG are now commercially available from
Eloquest Healthcare in the United States. The device received
510(k) clearance from the FDA in March and is now available nationwide.
Eloquest Healthcare is the exclusive distributor of the dressings in the
United States and Canada.
To learn more or request a sample visit, www.ReliaTectPostOp.com
or contact Eloquest Healthcare customer service at 1-877-433-7626.
About Eloquest Healthcare
Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale
Pharma Group, Inc. that is focused specifically on serving hospitals,
their healthcare practitioners, and patients. Eloquest Healthcare helps
deliver safer, more compassionate care by providing intuitive,
cost-effective solutions that complement treatment protocols. More
information can be found at www.eloquesthealthcare.com.
About Vancive Medical Technologies
Vancive Medical Technologies is a medical technology company with more
than three decades of expertise in adhesive chemistries and material
technologies for medical applications using pressure sensitive
adhesives. The company’s applications and technologies are an integral
part of products that are in daily use in medical facilities throughout
the world. Through long-term relationships with original equipment
manufacturers, industry-specific converters and leading universities,
Vancive Medical Technologies continually finds new ways to develop
products that can improve patient care. Vancive Medical Technologies is
an Avery Dennison business headquartered in Chicago, Illinois. To learn
more about Vancive Medical Technologies, visit www.vancive.averydennison.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in pressure-sensitive and
functional materials and labeling solutions for the retail apparel
market. The company’s applications and technologies are an integral part
of products used in every major industry. With operations in more than
50 countries and more than 25,000 employees worldwide, Avery Dennison
serves customers in the consumer packaging, graphical display,
logistics, apparel, industrial and healthcare industries. Headquartered
in Glendale, California, the company reported sales of $6.1 billion in
2016. Learn more at www.averydennison.com.
Contacts
Eloquest Healthcare Contact:
Matthew Stahl
Clinical Marketing
& Brand Director
248.586.8428
[email protected]
or
Vancive
Contacts:
Andrew Deckert
Global Marketing Communications
Manager
+1 224 374 2109
[email protected]
or
Barbara
Van Rymenam
Global Director, CHG Program
+32 (0)497 103233
[email protected]
.png)
